T1 hyperintensity on brain imaging subsequent to gadolinium-based contrast agent administration: what do we know about intracranial gadolinium deposition?

Other literature type, Article English OPEN
Hoggard, Nigel ; Roditi, Giles H. (2016)

There is growing evidence for the accumulation of gadolinium (Gd) in patients administered with intravenous Gd-based contrast agents, even in the absence of renal impairment. This review of the literature will discuss what has been found to date in cadaveric human studies, clinical studies of patients and from animal models. Evidence for the potential route of entry into the brain will be examined. The current state of knowledge of effects of Gd accumulation in the brain is discussed. We will then discuss what the possible implications may be for the choice of Gd-based contrast agents in clinical practice.
  • References (55)
    55 references, page 1 of 6

    1. European Medicines Agency. Assessment report for gadolinium-containing contrast agents 2010. In: Proced. No. EMEA/H/A-31/ 1097. [Accessed 21 April 2016]. Available from: http://www.ema.europa.eu/docs/en_ GB/document_library/Referrals_document/ gadolinium_31/WC500099538.pdf

    2. Do JG, Kim YB, Lee DG, Hwang JH. A case of delayed onset nephrogenic systemic fibrosis after gadolinium based contrast injection. Ann Rehabil Med 2012; 36: 880-6. doi: https://doi.org/10.5535/ arm.2012.36.6.880

    3. Thomson LK, Thomson PC, Kingsmore DB, Blessing K, Daly CD, Cowper SE, et al. Diagnosing nephrogenic systemic fibrosis in the post-FDA restriction era. J Magn Reson Imaging 2015; 41: 1268-71. doi: https://doi. org/10.1002/jmri.24664

    4. Sherry AD, Caravan P, Lenkinski RE. A primer on gadolinium chemistry. J Magn Reson Imaging 2009; 30: 1240-8. doi: https:// doi.org/10.1002/jmri.21966

    5. Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, Ellen Campbell M, Hauschka PV, Hannigan RE, et al. Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics 2009; 1: 479-88. doi: https://doi.org/10.1039/ b905145g

    6. White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006; 41: 272-8. doi: https://doi.org/10.1097/01. rli.0000186569.32408.95

    7. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1. doi: https://doi. org/10.1016/S0140-6736(00)02694-5

    8. Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 2005; 46: 763-5. doi: https://doi. org/10.1053/j.ajkd.2005.08.008

    9. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-8. doi: https://doi.org/10.1093/ ndt/gfk062

    10. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-62. doi: https://doi. org/10.1681/ASN.2006060601

  • Metrics
    No metrics available
Share - Bookmark